Looking good, we are producing larger quanities of Ropren than estimated and likely to be selling it for more than expected.
All we need now is orders and pricing confirmation and we are off.
BTW can we assume that the commitment to quarterly orders from Dr Vladimir Agishev will be at US$1125.
Hard to see it any lower now that we have the US$1125 figure mentioned.
annual report, page-20
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
